- Molecular NameMiglitol
- SynonymNA
- Weight207.226
- Drugbank_IDDB00491
- ACS_NO72432-03-2
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-2.37
- pka5.9
- LogD (pH=7, predicted)-2.38
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)0.66
- LogSw (predicted, AB/LogsW2.0)5333.63
- Sw (mg/ml) (predicted, ACD/Labs)778.83
- No.of HBond Donors5
- No.of HBond Acceptors6
- No.of Rotatable Bonds3
- TPSA104.39
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn oral anti-diabetic drug that acts by inhibiting the ability of the patient to breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.
- Absorption_value100.0
- Absorption (description)Absorption of miglitol is saturable at high doses with 25 mg being completely absorbed while a 100-mg dose is only 50-70% absorbed. No evidence exists to show that systemic absorption of miglitol adds to its therapeutic effect.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding4.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmNegligible (<4.0%)
- Half life2 h
- ExcretionRenal (95%)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityUnlike sulfonylureas or insulin, an overdose will not result in hypoglycemia. An overdose may result in transient increases in flatulence, diarrhea, and abdomi-nal discomfort. Because of the lack of extra-intestinal effects seen with miglitol, no serious systemic reactions are expected in the event of an overdose.
- LD50 (rat)N/A
- LD50 (mouse)N/A